Azithromycin

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Mycobacterium Avium-Intracellulare Infection

Conditions

Mycobacterium Avium-Intracellulare Infection, HIV Infections

Trial Timeline

— → —

NCT ID

NCT00002089

About Azithromycin

Azithromycin is a pre-clinical stage product being developed by Pfizer for Mycobacterium Avium-Intracellulare Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00002089. Target conditions include Mycobacterium Avium-Intracellulare Infection, HIV Infections.

What happened to similar drugs?

3 of 8 similar drugs in Mycobacterium Avium-Intracellulare Infection were approved

Approved (3) Terminated (1) Active (4)

✅clarithromycin, rifabutinPfizerApproved

🔄Ethambutol hydrochloride + Clarithromycin + AzithromycinPfizerPhase 3

✅AzithromycinPfizerApproved

✅Azithromycin + Rifabutin/rifampinPfizerApproved

🔄ALIS + Azithromycin + Ethambutol + ELCInsmedPhase 3

🔄ALIS + Azithromycin + Ethambutol + ELC (matching placebo for ALIS)InsmedPhase 3

🔄LAI (Liposomal Amikacin for Inhalation) 590 mgInsmedPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00002089	Pre-clinical	Completed	—	—	Mycobacterium Avium-Intracellulare Infection
NCT00002309	Pre-clinical	Completed	—	—	Mycobacterium Avium-Intracellulare Infection
NCT00002344	Phase 1	Completed	—	—	Bacterial Infections
NCT00002082	Pre-clinical	Completed	—	—	Cryptosporidiosis
NCT00002139	Phase 1	Completed	—	—	Bacterial Infections
NCT00002328	Pre-clinical	Completed	—	—	Cryptosporidiosis
NCT00002085	Pre-clinical	Completed	—	—	Mycobacterium Avium-Intracellulare Infection
NCT00002090	Pre-clinical	Completed	—	—	Mycobacterium Avium-Intracellulare Infection
NCT01919996	Phase 2	Terminated	Dec 1, 2013	Nov 1, 2015	Pharyngitis
NCT00871494	Phase 3	Completed	May 1, 2009	Nov 1, 2010	Pelvic Inflammatory Disease
NCT00809328	Phase 3	Completed	Feb 1, 2009	Mar 1, 2010	Community Acquired Pneumonia (CAP)
NCT00939185	Pre-clinical	Completed	Apr 1, 2007	Jan 1, 2009	Respiratory Tract Infections
NCT00229944	Phase 3	Completed	Dec 1, 2002	May 1, 2004	Cholera
NCT01227395	Pre-clinical	Completed	Jul 1, 2002	Mar 1, 2012	HIV Infection
NCT00599079	Approved	Completed	Feb 1, 1993	May 18, 2017	Mycobacterium Avium Complex Lung Disease

Competing Products

20 competing products in Mycobacterium Avium-Intracellulare Infection

See all competitors

Product	Company	Stage	Hype Score
Trifluridine	Amgen	Pre-clinical	26
clarithromycin, rifabutin	Pfizer	Approved	43
Azithromycin	Pfizer	Pre-clinical	26
Ethambutol hydrochloride + Clarithromycin + Azithromycin	Pfizer	Phase 3	40
Azithromycin	Pfizer	Pre-clinical	26
Azithromycin	Pfizer	Pre-clinical	26
Azithromycin	Pfizer	Approved	43
Tigecycline	Pfizer	Phase 2	35
Azithromycin + Rifabutin/rifampin	Pfizer	Approved	43
ALIS + Azithromycin + Ethambutol + ELC	Insmed	Phase 3	37
ALIS + Azithromycin + Ethambutol + ELC (matching placebo for ALIS)	Insmed	Phase 3	37
LAI plus multi-drug regimen	Insmed	Phase 2	32
Liposomal amikacin for inhalation (LAI) + placebo	Insmed	Phase 2	32
LAI (Liposomal Amikacin for Inhalation) 590 mg	Insmed	Phase 3	37
Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) + Ceftriaxone for Injection + Amoxicillin + Azithromcyin + clarithromycin + Clofazimine + Ethambutol + Amikacin Injection + tigecycline + Imipenem + Cilastatin + Cefoxitin + Amikacin (Inhalation) + linezolid + Trimethoprim / Sulfamethoxazole + Doxycycline + moxifloxacin + bedaquiline + Rifabutin	Innoviva	Phase 2	36
Molgramostim nebulizer solution	Savara	Phase 2	21
Inhaled molgramostim + Antimycobacterial regimen	Savara	Phase 2	29
Epetraborole + Epetraborole + Placebo + Placebo	AN2 Therapeutics	Phase 2	32
SPR720 + Placebo + Open-label Standard of Care	Spero Therapeutics	Phase 2	17
RHB-204 + Placebo	RedHill Biopharma	Phase 3	22